RNTX stock forecast, quote, news & analysis
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments... Show more
Why Rein Therapeutics (RNTX) Stock Is Down -21.8% in the Last 30 Days
Key Takeaways
- Rein Therapeutics (RNTX) shares fell roughly 21.8% over the past 30 days, declining from about $0.79 to $0.62, with a sharp single-day selloff in mid-October on elevated volume.
- The move reflects the combination of a dilutive financing disclosure and persistent trading below the $1.00 threshold that has kept Nasdaq minimum-bid-price compliance concerns in focus.
- Rein remains a pre-revenue, clinical-stage biopharmaceutical company whose valuation is tied almost entirely to its lead program, LTI-03 for idiopathic pulmonary fibrosis (IPF).
- Analyst coverage remains constructive, with Maxim Group reiterating a Buy rating and a $4.00 price target in late October despite the share-price weakness.
- Over the same stretch, the broader narrative has been shaped by cash runway, dilution risk, and upcoming Phase 2 clinical milestones rather than revenue or earnings growth.
- For more detail on this ticker's valuation and outlook, explore Price Targets, Earnings, and Forecast.
- To see how automated strategies are positioned across the market, explore Trending AI Robots.
Rein Therapeutics (RNTX) Company Overview and Market Position
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on orphan pulmonary and fibrosis indications with limited or no effective treatment options. Formerly known as Aileron Therapeutics, the company adopted its current name and Nasdaq ticker in January 2025. Its lead candidate, LTI-03, is an inhaled synthetic peptide in a Phase 2 trial (RENEW) for idiopathic pulmonary fibrosis (IPF) and carries Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. The pipeline also includes LTI-01, which has completed Phase 1b and Phase 2a studies for loculated pleural effusion. Because the company generates no product revenue, investors follow the stock primarily for clinical-trial readouts, regulatory milestones, and financing developments.
Rein Therapeutics (RNTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RNTX declined approximately 21.8%, from a closing price of $0.79 on October 9, 2026 to $0.62 by November 9, 2026. The most notable single session came on October 14, when shares dropped more than 20% on volume well above the prior daily average before stabilizing in the $0.55–$0.75 range. Looking further back, the trend is similarly negative: over the last quarter, shares fell roughly 17%, from about $0.75 in late August to $0.62, extending a longer slide that has kept the stock in penny-stock territory and below its 50-day and 200-day moving averages.
What Drove RNTX Stock Price in the Last 30 Days
The dominant catalyst was the October 14 decline, which coincided with the company's SEC disclosure of a $25.6 million issuance of common units in a private, exempt financing transaction. Dilutive capital raises weigh heavily on clinical-stage biotechs with thin trading liquidity, and the sharp, high-volume move suggested investors were repricing the additional share supply. The selloff also reinforced an existing concern: RNTX has been trading below the $1.00 Nasdaq minimum bid price for an extended period, and the company received a delisting notice in August 2026 related to that requirement. Offsetting these pressures somewhat, Maxim Group reiterated a Buy rating with a $4.00 price target on October 23, 2026, and H.C. Wainwright has maintained a Buy rating on the shares. Still, with no product revenue and ongoing cash burn, financing and dilution risk have remained the primary near-term drivers of sentiment.
What Drove RNTX Stock Performance Over the Last Quarter
Over the last quarter, the larger narrative has centered on funding runway and clinical execution. The company reported second-quarter 2026 results in mid-August with a narrower-than-expected loss, and it received FDA Fast Track designation for LTI-03 in IPF that same month. It also published Phase 1b biomarker data in Nature Communications and presented at the European Respiratory Society Congress, events that highlighted the scientific progress of LTI-03. However, these positive developments were outweighed by balance-sheet concerns: the Nasdaq delisting notice, the continued sub-$1 share price, and a series of financing activities, including a $50 million public offering earlier in 2026, have kept dilution at the center of investor focus and pressured the stock's multi-month trend.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots across the platform. Tickeron provides hundreds of automated trading robots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section, making it easier for users to cut through the noise. The bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term swing approaches to longer-horizon models, each with its own risk profile and track record. For traders looking to supplement their own analysis with data-driven, automated signals, the section provides a focused starting point for discovering strategies that align with their objectives.
RNTX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors ahead. First, the company's third-quarter 2026 earnings report, scheduled for mid-November, will provide an update on cash position, operating expenses, and the company's projected runway. Second, enrollment progress and any interim updates from the Phase 2 RENEW trial of LTI-03 in IPF remain the key clinical catalysts. Third, Nasdaq listing compliance remains a live issue, as any path to restoring the minimum bid price may involve a reverse stock split or further capital raises. Fourth, additional financing announcements and their terms will continue to shape dilution expectations. Finally, broader sector sentiment toward clinical-stage, pre-revenue biotechs and the competitive landscape in IPF will influence how the market values these catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RNTX's Stochastic Oscillator is sitting in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RNTX's RSI Indicator exited the oversold zone, 34 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +1.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNTX advanced for three days, in 177 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RNTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNTX as a result. In 87 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for RNTX turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 37 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
RNTX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RNTX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.191) is normal, around the industry mean (3.498). P/E Ratio (-0.365) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. RNTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology